INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE INNOVATION
journal homepage: www.ijphi.com

OPEN ACCESS

Review Article

Cobenfy: Mechanism of Action, Clinical Trials, Side Effects, and Toxicity

Ankit Kumar Singh[1], Neeraj Kumar Verma[*2]

[1]Institute of Pharmaceutical Sciences, Shri Ramswaroop Memorial University, Barabanki, UP, India

[2]Institute of Pharmacy, Shri Ramswaroop Memorial University, Barabanki, UP, India

Article Info

Article history:

Manuscript ID:

IJPHI0320242025
Received: 03-March -2025
Revised :20- March -2025
30- March -2025

Accepted: 30- March 2025
Available online: March 2025

Keywords:
Muscarinic Agonist, Xanomeline, Trospium Chloride, Schizophrenia Treatment, FDA Approval, Clinical Efficacy, Adverse Effects, Hepatic Impairment, Urinary Retention, Angioedema

Corresponding Author:
neerajverma563@gmail.com

Abstract

Cobenfy, named xanomeline and trospium chloride, is a totally novel antipsychotic medication that has recently been approved to treat Schizophrenia. Unlike the classical antipsychotics that primarily act on the dopamine receptor, Cobenfy is working on modulation of muscarinic receptors through a novel mechanism. This novel mechanism is targeted at the limitations or side effects with the use of conventional antipsychotic drugs. One of the active constituent compounds of Cobenfy is Xanomeline which happens to be a selective muscarinic acetylcholine receptor agonist targeting M1 and M4 receptors in the central nervous system. This modulation aids in stabilizing neurotransmitter activity, hence providing therapeutic benefits to patients afflicted with Schizophrenia. The other compound is Trospium chloride which happens to act as a peripherally restricted muscarinic antagonist. This would limit peripheral side effects as it blocks muscarinic receptors outside the central nervous system. A review paper would incorporate the multi-dimensional aspects of Cobenfy: its innovative mechanism of action, results of clinical trials, and side effect profile. In addition, the literature reviews related to toxicity concerns of this drug shall be covered to capture truly its profile in terms of safety and efficacy. It attempts to review the potential of Cobenfy as a promising new therapeutic option for Schizophrenia, providing a fresh insight into managing this complex and challenging mental health disorder. A further elaborate discussion on these aspects would make an effort toward enriching the understanding of Cobenfy and its future utilization in clinical practice.

Introduction

Cobenfy is a latest antipsychotic medication that has been approved for the treatment of Schizophrenia. In contrast to the traditional old antipsychotics aimed at dopamine receptor blockage, the mechanism of action in the case of Cobenfy is related to muscarinic receptors. This unique approach promises to eliminate the problems and negative impact accompanying the traditional antipsychotic drugs.[1]Cobenfy contains two active substances: xanomeline is an agonist at muscarinic acetylcholine receptor (mAChR) and trospium chloride is a muscarinic antagonist. Xanomeline is a selective M1 and M4 muscarinic antagonist acting in the central nervous system for changing the activity of neurotransmitters in order to be effective against Schizophrenia.[2]On the other hand, the action of Trospium chloride is peripherally where there is a reduction of side effects because of blocking muscarinic receptors outside the central nervous system. The Cobenfy has been granted approval based on the accomplishments recorded from the results of the EMERGENT clinical program. The research found to be statistically significant in reducing the symptoms of Schizophrenia and really set up a safe and tolerable profile across acute and long-term trials.[3]This drug has been effective in improvements of positive and negative symptoms of Schizophrenia but without the common side effects that are attributed to such traditional antipsychotics, such as weight gain and movement disorders. Cobenfy is an advanced form of therapy for Schizophrenia, and with this comes a new horizon of treatment that seems favorable regarding side effects. This new compound works exclusively on the receptors involving dopamine and has provided very promising clinical results, which can significantly enhance the quality of life for patients subjected to this enormously complex and taxing mental disorder.[4]

Mechanism of Action

Cobenfy is a new therapeutic agent for Schizophrenia because the two synergistic components, xanomeline and trospium chloride, will act in concert to maximize therapeutic effect with minimal side effects, an often-cited problem in traditional antipsychotics.[5]

Xanomeline

Xanomeline is a potent M1 and M4 muscarinic acetylcholine receptor (mAChR) agonist. It is largely confined to the CNS where its administration leads to some striking effects on neurotransmitter release. Indirectly, xanomeline influences the dopamine pathways typically affected by Schizophrenia.[6]

M1 Receptors: Activation of M1 receptors enhances cognitive function and memory. This might have useful potential to alleviate the cognitive impairments most commonly seen in Schizophrenia.[6]

M4 Receptors: Activation of M4 receptors could prevent dopaminergic release. It has antipsychotic action due to normalization of dopaminergic release without the direct antagonism at dopamine receptors, thus minimizing the risk of extrapyramidal side effects or movement disorders.[6]

Trospium Chloride

The drug which is the muscarinic antagonist that mainly operates by peripheral mechanisms is trospium chloride. This is because it cannot penetrate through the blood-brain barrier. This leads to a blockade of peripheral muscarinic receptors, which indirectly decreases cholinergic side effects caused by agonists at muscarinic receptors, including gastrointestinal disturbances and salivation.[7]

Peripheral Action: Trospium chloride would minimize the activation of the muscarinic receptor in peripheral tissues; hence, there would be a reduction in side effects like excessive salivation, sweating, and changes in gastrointestinal motility.[7]

Safety Profile: This peripheral blockade ensured keeping the safety profile of Cobenfy by maximizing the therapeutic benefits of xanomeline without sacrificing patient comfort and adherence to treatment.[7]

Clinical Studies

The clinical program of EMERGENT has explored Cobenfy with utmost and extensive depth, including acute and long-term clinical trials. In this experiment, the primary objectives of Cobenfy in the management of Schizophrenia have been to ascertain therapeutic benefits and safety profile.[8]

Acute Studies

The acute studies were part of the clinical program of EMERGENT. These included three placebo-controlled efficacy and safety studies.[8]

Short-term trials of Cobenfy in the treatment of Schizophrenia: These studies investigated the short-term effects of Cobenfy on Schizophrenia symptoms. The results found statistically significant reductions in both positive and negative symptoms of Schizophrenia.[8]

Positive symptoms include hallucinations and delusions, while negative symptoms include social withdrawal and lack of motivation. The significant improvements found in these studies illustrate Cobenfy's potential to effectively treat the core symptoms of Schizophrenia.[8]

Long-term trials

The long-term stage of the EMERGENT clinical program included two open-label studies evaluating the safety and tolerability of Cobenfy over a year or more.[8]These open-label studies provided information regarding long-term efficacy and the drug's long-term safety profile. The outcomes achieved in the trials were such that Cobenfy was well tolerated in most patients and showed a better side effect profile compared to other traditional antipsychotics. One crucial finding of the EMERGENT clinical study was that Cobenfy did not cause the most common side effects of conventional antipsychotics such as weight gain and movement disorders.[8]The most common side effects were nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, and dizziness.[8These side effects are generally mildest to moderate in intensity and are controlled by proper medical care.[8]The magnitude and nature of symptom reduction plus the generally beneficial side-effect profile noted in these studies confirm Cobenfy as an emerging treatment for patients suffering from Schizophrenia.[8]

Side Effects

Cobenfy, the mechanism of action by which it works having been unprecedented, has a less adverse side effect profile compared with most traditional antipsychotics; this places the drug as a strong candidate for patients who have experienced debilitating side effects from conventional treatments.

Common Side Effects

Gastrointestinal and cardiovascular adverse effects are the most frequently encountered with Cobenfy. These are generally mild to moderate in intensity and often manageable with proper medical interventions:

Nausea and Vomiting: The patient may have an upset stomach or nausea that, on rare occasions, leads to vomiting. [9,10,11]

Indigestion and Abdominal Pain: There can be gastrointestinal discomfort in the form of indigestion and abdominal pain. [9,10,11]

Constipation and Diarrhea: There are usually changes in bowel habits in the form of constipation or diarrhea. [9,10,11]

Hypertension and Increased Heart Rate: Some patients experience heightened blood pressure or an increased heart rate. [9,10,11]

Dizziness: You may feel dizziness or lightheadedness, especially when first starting the medication or at the time of increasing the dose. [9,10,11]

Lack of Typical Atypical Antipsychotic Side Effects

Cobenfy lacks most of the typical boxed warnings that commonly exist with use of atypical antipsychotics. Most conventional antipsychotics lead to:

Weight Gain: Most drugs in the antipsychotic class are associated with the potential for significant weight gain. Cobenfy does not suffer from this. [9,10,11]

Metabolic Syndrome: It encompasses such a condition as including excess glucose in the blood, excess body fat around the waist, and abnormal cholesterol levels, which are not as prominent in Cobenfy's history. [9,10,11]

Extrapyramidal Symptoms: The extrapyramidal symptoms like those involving tremors and rigidity, most often seen with the use of dopamine antagonist medications, are much less common among Cobenfy patients. [9,10,11]

Less Common Adverse Effects

Though Cobenfy is reported to be well tolerated, there are a few less common, but nonetheless very important, adverse effects:

Urinary Retention: The peripheral action of trospium chloride may cause urinary retention. [9,10,11]

Angioedema: It is a rare and potentially dangerous condition characterized by swelling under the skin, which may be very dangerous if it reaches the throat and airways. [9,10,11]

Decreased Gastrointestinal Motility: This is decreased stomach and intestines activity which impairs digestion. [9,10,11]

Generally, the side-effect profile of Cobenfy represents an appreciable improvement over many antipsychotics currently available. This would represent a much better option for the treatment of the schizophrenic patient. Continuous monitoring and educating the patients will be important to properly manage and prevent these side effects. [9,10,11]

Toxicity

Although generally very well tolerated, Cobenfy carries with it specific toxicity concerns that must be taken very seriously. The prescribing information of Cobenfy includes specific warnings and cautions to ensure safety for the patient.[12]

Hepatic Impairment: Cobenfy is contraindicated in patients with known hepatic impairment. It runs the risk of an adverse drug reaction in pliver-damaged patients because the drug could probably hasten problems that are associated with pre-existing liver conditions. Patients with mild to severe liver impairment should be avoided using Cobenfy, with alternative treatments being considered for patients.[12]

Possible Toxic: The prescribing information draws attention to a number of possible toxicities associated with Cobenfy. These include:

Tachycardia: Some patients may present with tachycardia, an increased heart rate, which is worrying, especially in patients who are at risk from cardiovascular disease.[12]

Urinary Retention: The trospium chloride portion of the Cobenfy drug works by blocking the action of muscarinic receptors in the bladder; this leads to urinary retention, a common side effect with having trouble urinating sometimes requiring medical attention.[12]

Reduced Gastric Motility: Reduced gastric motility can lead to symptoms including constipation and slowed gastric emptying, which can lead to digestive issues.[12]

Angioedema: Although rarely, Cobenfy can also result in angioedema, which is the swelling under the skin, commonly noted on the face and lips. This can be a very critical condition if it affects the airways and breathing.[12]

Long-term Studies

Although the EMERGENT clinical program brought sufficient information regarding the short-term and long-term safety of Cobenfy, long-term studies are necessary to really understand its toxicity profile. Long-term studies will help identify any delayed adverse effects and ensure the drug's safety over extended use.In a nutshell, Cobenfy offers a new, promising treatment for Schizophrenia with a favorable side effect profile; however, the patient must be closely monitored in such instances of potential toxicities, especially those suffering from hepatic impairment. The healthcare provider must be keen to assess and, accordingly, address these risks to ensure safety and efficacy in treatment.[13]

Conclusion

Cobenfy is the breakthrough of antipsychotics drugs: for the first time in clinical history, a new pharmacological mechanism of action was introduced - one of the most unusual and promising for the correction of the psyche, as it gives a possibility to start new methods not depending on dopamine receptors used in the classical drugs. Xanomeline, an agonist to muscarinic acetylcholine receptors, used together with the antagonist trospium chloride in the drug "Cobenfy", represents a new unique treatment for Schizophrenia, which both helps manage its core symptoms, positive and negative manifestations, without causing common negative manifestations usually characterizing conventional antipsychotics. The clinical trials under the EMERGENT program have established Cobenfy's efficacy in reducing schizophrenic symptoms with a favorable side-effect profile. Unlike traditional antipsychotics, which bring about weight gain, metabolic syndrome, and extrapyramidal symptoms, Cobenfy has been well-documented to avoid these problems and represents a more tolerable treatment for patients. Still, the journey of Cobenfy is not concluded with its approval and current clinical use. Continued research and development will be necessary for

complete understanding of its long-term safety and efficacy. Long-term studies are necessary to explore any kind of delayed adverse effects, how to optimize the usage guidelines, and what all these implications may entail for this medication. Its application in other psychiatric disorders and different patient populations can further broaden the therapeutic benefits.

Further research into personalized medicine could help Cobenfy prove itself through tailor-made treatments suited to specific genetic and molecular profiles. Researchers, healthcare providers, and regulatory bodies will come together to ensure that Cobenfy's use proves both safe and effective in enhancing the quality of life for Schizophrenia patients. Conclusion Cobenfy is a treatment that may rejuvenate a lot of Schizophrenia cases, bringing favorable management of the complex and debilitating mental disorder.

Ethical approval : NA

Informed consent : Not Applicable.

Funding : No funding

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare no conflict of interest among themselves. The authors alone are responsible for the content and writing of this article.

Financial interests:

The authors declare they have no financial interests

References:

1. "FDA Approves Drug with New Mechanism of Action for Treatment of ...." 26 Sept. 2024, https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-Schizophrenia.

2. "Cobenfy for Schizophrenia: Dosage, Side Effects, Warnings and more ...." 30 Sept. 2024, https://www.drugs.com/cobenfy.html.

3. "Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for ...." 24 Feb. 2021, https://www.nejm.org/doi/full/10.1056/NEJMoa2017015.

4. "First new type of treatment for Schizophrenia in decades - NPR." 27 Sept. 2024, https://www.npr.org/sections/shots-health-news/2024/09/27/g-s1-25089/karxt-cobenfy-Schizophrenia-psychosis-fda.

5. "Cobenfy: The First New Schizophrenia Drug in Decades - Verywell Health." 02 Oct. 2024, https://www.verywellhealth.com/cobenfy-Schizophrenia-drug-fda-approval-8719646.

6. "The M1/M4 preferring muscarinic agonist xanomeline modulates functional ...." 20 Dec. 2020, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115158/.

7. "Muscarinic Antagonists - StatPearls - NCBI Bookshelf." 08 May. 2023, https://www.ncbi.nlm.nih.gov/books/NBK557541/.

8. "COBENFY represents the first new pharmacological approach to treat ...." https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2024/bmy-cobenfy.pdf.

9. "New Schizophrenia Drug Cobenfy (Xanomeline and Trospium Chloride) Gets ...." 27 Sept. 2024, https://www.everydayhealth.com/mental-health-conditions/fda-approves-new-type-of-Schizophrenia-drug/.

10. "US approves Schizophrenia drug with new mode of action." https://www.chemistryworld.com/news/us-approves-Schizophrenia-drug-with-new-mode-of-action/4020277.article.

11. "Behind the rise of BMS' Cobenfy, the first new Schizophrenia drug in ...." 26 Sept. 2024, https://www.pharmavoice.com/news/bms-karxt-Schizophrenia-fda-karuna-miller/728227/.

12. "Drug safety: The concept, inception and its importance in patients ...." 09 May. 2014, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908051/.

13. "Mitigating long-term and delayed adverse events associated with cancer ...." 25 May. 2023, https://www.nature.com/articles/s41571-023-00776.